Surgical treatment of metastatic germ cell cancer

doi:10.1016/j.ajur.2020.05.007

Asian Journal of Urology, 2021, 8 (2): 155-160 doi: 10.1016/j.ajur.2020.05.007

Reviews

Current Issue | Archive | Adv Search

Surgical treatment of metastatic germ cell cancer

Andreas Hiester(

),Peter Albers

Department of Urology, University of Duesseldorf, Medical Faculty, Heinrich-Heine-University,Duesseldorf, Germany

Abstract
Related Citation (0)

Download:

HTML

PDF (878KB)
Export: BibTeX | EndNote (RIS)

Abstract

Among young men between the ages of 15 and 40 years, germ cell cancer is the most common solid tumor [1]. The worldwide incidence of germ cell cancer is 70 000 cases. Compared to all solid tumors of men, germ cell cancer accounts for 1% of all male tumors. Nevertheless, the mortality of this rare tumor entity is about 13% since 9507 patients died worldwide of germ cell cancer. The improvement in survival of germ cell cancer patients is due to a multimodal treatment of germ cell cancer including cisplatin-based chemotherapy and surgery leading to higher cure-rates even in advanced stages [1], whereas the increasing incidence of germ cell cancers cannot be thoroughly explained. In this article we review the current indications for surgery in metastatic germ cell cancers, highlight the strength and weaknesses of techniques and indications and raise the question how to improve surgical treatment in metastatic germ cell cancer.

Key words： Germ cell cancer Metastatic germ cell cancer Retroperitoneal lymphnode dissection Retroperitoneal surgery

Received: 26 November 2019 Available online: 01 June 2020

Corresponding Authors: Andreas Hiester E-mail: andreas.hiester@med.uni-duesseldorf.de

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Andreas Hiester
	Peter Albers

TRENDMD:

Cite this article:

Andreas Hiester,Peter Albers. Surgical treatment of metastatic germ cell cancer[J]. Asian Journal of Urology, 2021, 8(2): 155-160.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2020.05.007 OR http://www.ajurology.com/EN/Y2021/V8/I2/155

Stage grouping for germ cell cancer (European Society of Medical Oncology, ESMO) [37].

Flow chart of treatment of germ cell cancer according to the NCCN and EAU Guideline [1,9]. The indications for surgery are highlighted (yellow). (A) The clinical and diagnostic work-up of seminoma patients; (B) The clinical and diagnostic work-up of non-seminoma patients. BEP, bleomycin, etoposide, cisplatin; EP, etoposied, cisplatin; PEI, cisplatin, etoposide, ifosfamide; FDG, fluorodeoxyglucose; PET, positron emission tomography; CT, computertomography; PC-RPLND, postchemotherapy retroperitoneal lymphnode dissection; ns-RPLND, nerve-sparing retroperitoneal lymphnode dissection; CS IS, clinical stage 1S; VIP, vinblastine, ifosfamide, cisplatin; N1-N3, lymphonodal metastasis WHO classification; NCCN, the National Comprehensive Cancer Network; EAU, the European Association of Urology. ?preferred; ??only selected cases.

Graphical description of anatomical boundaries of right and left template PC-RPLND. Template resection of the right side includes the precaval, caval, paracaval, retrocaval and inter-aortocaval regions, as well as the region lateral of the common iliac vessels. Template resection of the left side includes pre-aortic, retro-aortic and para-aortic lymph nodes. The ipsilateral ureter represents the caudal and lateral boundary of resection; in patients without retrocrural or suprahilar lymph nodes, the renal vein is described as the cranial and the crus of the diaphragma as the posterior resection boundary. PC-RPLND, post chemotherapy setting retroperitoneal lymphnode dissection.

[1]	Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on testicular cancer:2015 update. Eur Urol 2015; 68:1054e68.
[2]	C M. Tumeurs du testicule. Paris: These; 1906.
[3]	Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol 2017; 35:3525e8.
[4]	International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15:594e603.
[5]	Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol 2018; 29:341e6.
[6]	Nayan M, Jewett MA, Anson-Cartwright L, Bedard PL, Moore M, Chung P, et al. The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Can Urol Assoc 2016; 10:204e9.
[7]	Adra N, Althouse SK, Liu H, Brames MJ, Hanna NH, Einhorn LH, et al. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol 2016; 27:875e9.
[8]	Lusch A, Albers P. Residual tumor resection (RTR). World J Urol 2017; 35:1185e90.
[9]	Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Testicular cancer, version 2.2015. J Natl Compr Canc Netw 2015; 13:772e99.
[10]	óShaughnessy MJ, Feldman DR, Carver BS, Sheinfeld J. Late Relapse of testicular germ cell tumors. Urol Clin North Am 2015; 42:359e68.
[11]	Hiester A, Nini A, Fingerhut A, Grosse Siemer R, Winter C, Albers P, et al. Preservation of ejaculatory function after postchemotherapy retroperitoneal lymph node dissection (PCRPLND)in patients with testicular cancer: template vs.bilateral resection. Front Surg 2018;5:80. https://doi.org/10.3389/fsurg.2018.00080.
[12]	Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 2007; 110:1235e40.
[13]	Heidenreich A, Pfister D, Witthuhn R, Thuer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol 2009; 55:217e24.
[14]	Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol 2019; 202:272e81.
[15]	Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26:2966e72.
[16]	Heidenreich A, Paffenholz P, Nestler T, Pfister D. Primary and postchemotherapy retroperitoneal lymphadenectomy for testicular cancer. Oncol Res Treat 2018; 41:370e8.
[17]	Mano R, Di Natale R, Sheinfeld J. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol 2019; 37:209e18.
[18]	Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007; 25:5597e602.
[19]	Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germcell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005; 23:2781e8.
[20]	Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol 2007; 177:937e43.
[21]	Ghandour RA, Singla N, Bagrodia A. Management of stage II germ cell tumors. Urol Clin North Am 2019; 46:363e76.
[22]	Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, Herr H, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995; 13:2700e4.
[23]	Kondagunta GV, Sheinfeld J, Mazumdar M, Mariani TV, Bajorin D, Bacik J, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004; 22:464e7.
[24]	Behnia M, Foster R, Einhorn LH, Donohue J, Nichols CR. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Canc 2000; 36:472e5.
[25]	Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53:497e513.
[26]	Cary C, Jacob JM, Albany C, Masterson TA, Hanna NH, Einhorn LH, et al. Long-term survival of good-risk germ cell tumor patients after postchemotherapy retroperitoneal lymph node dissection: a comparison of BEP x 3 vs. EP x 4 and treating institution. Clin Genitourin Canc 2018;16:e307e13. https://doi.org/10.1016/j.clgc. 2017. 10. 008.
[27]	Daneshmand S, Albers P, Fossa SD, Heidenreich A, Kollmannsberger C, Krege S, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol 2012; 62:867e76.
[28]	Paffenholz P, Nestler T, Hoier S, Pfister D, Hellmich M, Heidenreich A. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer. Urol Oncol 2019;37:809.e9e809.e18. https://doi.org/10.1016/j.urolonc. 2019. 07. 021.
[29]	Lorch A. Management of refractory germ cell cancer. Am Soc Clin Oncol Educ Book 2018; 38:324e9.
[30]	Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28:1706e13.
[31]	Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, et al. Surgical management of patients with advanced germ cell tumors following salvage chemotherapy: memorial Sloan Kettering Cancer Center (MSKCC) experience. Urology 2019; 124:174e8.
[32]	Lorch A, Albers P. [Update on first-line and relapse chemotherapy for testicular cancer]. Der Urologe Ausg A 2013; 52:1547e55.[Article in German].
[33]	Ghodoussipour S, Daneshmand S. Postchemotherapy resection of residual mass in nonseminomatous germ cell tumor. Urol Clin North Am 2019; 46:389e98.
[34]	Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Canc 2006; 94:820e7.
[35]	Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008; 26:5524e9.
[36]	Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 2002; 95:520e30.
[37]	Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, et al. Testicular seminoma and non-seminoma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi125e32. https://doi.org/10.1093/annonc/mdt304.